|1.||Uyar, Ruhi: 1 article (08/2004)|
|2.||Kabadere, Selda: 1 article (08/2004)|
|3.||Yaz, Gökçen: 1 article (08/2004)|
|4.||Oztopçu, Pnar: 1 article (08/2004)|
|5.||Durmaz, Ramazan: 1 article (08/2004)|
|6.||Shpilberg, Ofer: 1 article (01/2003)|
|7.||Hayon, Tamar: 1 article (01/2003)|
|8.||Levy, Etti: 1 article (01/2003)|
|9.||Nathan, Ilana: 1 article (01/2003)|
|10.||Dvilansky, Alexander: 1 article (01/2003)|
|1.||Breast Neoplasms (Breast Cancer)
01/01/1978 - "Clinical trial of nafoxidine in advanced breast cancer."
11/01/1977 - "Clinical trial of nafoxidine in adrenalectomized patients with advanced breast cancer."
04/06/1974 - "The synthetic non-steroidal antioestrogen nafoxidine (U-11, 100A) was given by mouth to 52 women with locally advanced or metastatic breast cancer, in 85% of whom the disease had become resistant to, or relapsed after, previous endocrine treatment. "
04/06/1974 - "Antioestrogens in treatment of breast cancer: value of nafoxidine in 52 advanced cases."
08/01/1972 - "Clinical trial of nafoxidine, an oestrogen antagonist in advanced breast cancer."
01/01/1979 - "Phase II study of nafoxidine in the therapy for advanced renal carcinoma."
04/01/1976 - "Therapeutic value of nafoxidine hydrochloride in the treatment of advanced carcinoma of the human breast."
11/01/1977 - "In patients with metastatic breast carcinoma, who have undergone adrenalectomy in the past, a therapeutic trial with Nafoxidine may be worthwhile particularly in patients who have demonstrable estrogen receptor in the tumor of those who have in the past shown regression of tumor after endocrine therapy."
07/01/1981 - "Treatment of renal carcinoma: a phase III randomized trial of oral medroxyprogesterone (Provera), hydroxyurea, and nafoxidine."
07/01/1981 - "Seventy patients with metastatic renal carcinoma were randomized to receive hydroxyurea, nafoxidine, or medroxyprogesterone (Provera) orally. "
12/01/1986 - "Nafoxidine prolonged the survival time of the rats injected with the tumor cells; complete regression of the tumor was observed when rats bearing a 3-day-old tumor were injected with this compound. "
02/01/1981 - "Estrogenic effects of nafoxidine on ovarian-dependent and independent mammary tumor lines in the mouse."
03/01/1976 - "Therapy with nafoxidine for patients suffering from postmenopausal ulcerated mammary cancer."
09/01/1973 - "Growth-stimulating effect of Nafoxidine on rat mammary tumor after ovariectomy."
11/01/1977 - "Of the four patients in whom estrogen receptor estimation was not done, two had, in the past, shown regression after endocrine therapy and they also showed regression of tumor with Nafoxidine therapy. "
|5.||Body Weight (Weight, Body)
05/01/1981 - "Nafoxidine also mimicked the effects of EB by reducing food intake, body weight, and carcass adiposity in OVX rats. "
05/01/1981 - "In nafoxidine-treated OVX rats, concurrent progesterone administration had no effect on adipose tissue LPL activity, but progesterone did increase food intake, body weight, and carcass fat content. "
03/01/1984 - "Beginning on the day of surgery, animals were injected daily for 5 days with 0.25, 5 or 25 micrograms/100 g body weight of nafoxidine or 5 mg MER-25 and sacrificed on the sixth day following castration. "
05/01/1994 - "Fifty regularly cycling guinea pigs were divided into five groups (five animals/group), of which three groups received 3 mg/kg body weight Nafoxidine, Centchroman, or Tamoxifen, respectively, on the 1st, 2nd, or 3rd day of pregnancy. "
06/01/1996 - "Estrogen was the most potent in reducing cholesterol levels in ovariectomized rats, whereas tamoxifen and nafoxidine were more effective than raloxifene in blocking gain in body weight. "
|4.||Estrogen Receptor Modulators (Antiestrogen)
|5.||Progesterone Receptors (Progesterone Receptor)
|7.||Ethinyl Estradiol (Estinyl)
|8.||Medroxyprogesterone Acetate (Depo-Provera)